PDF icon PDF herunterladen
Semin Respir Crit Care Med 2015; 36(02): 225-235
DOI: 10.1055/s-0035-1546752
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Microbiome and Emerging Pathogens in Cystic Fibrosis and Non–Cystic Fibrosis Bronchiectasis

Heather Green
1   Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
,
Andrew M. Jones
1   Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. März 2015 (online)

   Lizenzen und Reprints
Preview

Abstract

Chronic pulmonary sepsis is the predominant cause of morbidity for patients with cystic fibrosis (CF) and non-CF bronchiectasis. Previously it was thought that respiratory infection in these patients was mostly limited to a very small number of typical pathogens; however, in recent years there have been increasing reports of infection with other emerging potential pathogens including Burkholderia, Stenotrophomonas, Achromobacter, Ralstonia, Pandoraea, nontuberculous mycobacteria, and fungal species. Furthermore, culture-independent methodologies have established that the lungs of patients with CF and non-CF bronchiectasis comprise mixed microbiological communities of aerobic and anaerobic bacteria, fungal and viral species, collectively referred to as the lung microbiome. This article addresses the clinical relevance of emerging pathogens and the lung microbiome in CF and non-CF bronchiectasis.

Keywords

cystic fibrosis - non-CF bronchiectasis - microbiology - emerging pathogens - microbiome